Recent events
Recent events tied to this brand in public sources.
Back to profile7 entries
2026
Setara launches with $90 million in Series A financing
Setara launched with $90 million in Series A financing. Jazz Pharmaceuticals joined as a new shareholder following its acquisition of Actio Biosciences.
2021
FDA approves Xywav for idiopathic hypersomnia in adults
The FDA approved a new indication for Xywav to manage idiopathic hypersomnia in adults.
2021
Onera Health closes €10.5 million Series B funding round
Onera Health closed a €10.5 million Series B funding round led by Innovation Industries in collaboration with Invest-NL and existing investors. The company said it intends to use the funds for clinical studies and to further commercialize its sleep diagnostics and monitoring products in Europe and the United States.
2021
Jazz Pharmaceuticals completes acquisition of GW Pharmaceuticals
Jazz Pharmaceuticals announced that it completed its acquisition of GW Pharmaceuticals.
2021
Bionical Emas announces managed access program for JZP-458
Bionical Emas announced a Managed Access Program for Jazz Pharmaceuticals' medicinal product JZP-458, initially launching in select countries within Europe.
2021
Jazz Pharmaceuticals announces acquisition of GW Pharmaceuticals
Jazz Pharmaceuticals and GW Pharmaceuticals announced a definitive agreement for Jazz to acquire GW for $220 per American Depositary Share, in a transaction valued at $7.2 billion. The transaction was subject to shareholder, court and regulatory approvals and was expected to close in the second quarter of 2021.
2020
FDA grants accelerated approval for Zepzelca
The FDA granted accelerated approval for Zepzelca (lurbinectedin) to treat adults with metastatic small cell lung cancer whose disease progressed on or after platinum-based chemotherapy. Jazz Pharmaceuticals and PharmaMar secured the approval.